DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-05-04

AUTHORS

Riikka J. Lund, Kaisa Huhtinen, Jussi Salmi, Juha Rantala, Elizabeth V. Nguyen, Robert Moulder, David R. Goodlett, Riitta Lahesmaa, Olli Carpén

ABSTRACT

High-grade serous ovarian cancer is the most common ovarian cancer type. Although the combination of surgery and platinum-taxane chemotherapy provide an effective treatment, drug resistance frequently occurs leading to poor outcome. In order to clarify the molecular mechanisms of drug resistance, the DNA methylation and transcriptomic changes, associated with the development of drug resistance in high-grade serous ovarian cancer, were examined from patient derived malignant ascites cells. In parallel with large-scale transcriptome changes, cisplatin resistance was associated with loss of hypermethylation at several CpG sites primarily localized in the intergenic regions of the genome. The transcriptome and CpG methylome changes in response to cisplatin treatment of both sensitive and resistant cells were minimal, indicating the importance of post-translational mechanisms in regulating death or survival of the cells. The response of resistant cells to high concentrations of cisplatin revealed transcriptomic changes in potential key drivers of drug resistance, such as KLF4. Among the strongest changes was also induction of IL6 in resistant cells and the expression was further increased in response to cisplatin. Also, several other components of IL6 signaling were affected, further supporting previous observations on its importance in malignant transformation and development of drug resistance in ovarian cancer. More... »

PAGES

1469

References to SciGraph publications

  • 2014-05-29. Systems biology of cisplatin resistance: past, present and future in CELL DEATH & DISEASE
  • 2015-10-23. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer in NATURE REVIEWS CANCER
  • 2013-07-26. An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response in BMC GENOMICS
  • 2015-03-11. Prediction of resistance to chemotherapy in ovarian cancer: a systematic review in BMC CANCER
  • 2012-01-16. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling in ONCOGENE
  • 2012-10-03. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles in GENOME BIOLOGY
  • 1999-04-08. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer in ONCOGENE
  • 2016-02-27. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer in JOURNAL OF MOLECULAR MEDICINE
  • 2014-04-04. The role of vitamin D in reducing cancer risk and progression in NATURE REVIEWS CANCER
  • 2010-05-02. GREAT improves functional interpretation of cis-regulatory regions in NATURE BIOTECHNOLOGY
  • 2016-01-20. Can advanced-stage ovarian cancer be cured? in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2011-01-01. Integrative genomics viewer in NATURE BIOTECHNOLOGY
  • 2012-03-04. Fast gapped-read alignment with Bowtie 2 in NATURE METHODS
  • 2014-06-30. ChIPseek, a web-based analysis tool for ChIP data in BMC GENOMICS
  • 2008-09-30. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage in BMC MEDICAL GENOMICS
  • 2016-02-25. Epigenetic Silencing of the Key Antioxidant Enzyme Catalase in Karyotypically Abnormal Human Pluripotent Stem Cells in SCIENTIFIC REPORTS
  • 2012-10-03. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling in GENOME BIOLOGY
  • 2005-09-23. Expression of VDR and CYP24A1 mRNA in human tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-08-07. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors in GENOME MEDICINE
  • 2006-09-22. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2008-01-23. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2009-06-08. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer in BMC MEDICAL GENOMICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41598-017-01624-4

    DOI

    http://dx.doi.org/10.1038/s41598-017-01624-4

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1085131720

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/28473707


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cisplatin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "CpG Islands", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "DNA Methylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Resistance, Neoplasm", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Regulation, Neoplastic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kruppel-Like Factor 4", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ovarian Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transcriptome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.452861.c", 
              "name": [
                "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lund", 
            "givenName": "Riikka J.", 
            "id": "sg:person.01174612030.78", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174612030.78"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.410552.7", 
              "name": [
                "Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Huhtinen", 
            "givenName": "Kaisa", 
            "id": "sg:person.0770257425.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770257425.21"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.452861.c", 
              "name": [
                "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Salmi", 
            "givenName": "Jussi", 
            "id": "sg:person.01344256713.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344256713.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.410552.7", 
              "name": [
                "Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rantala", 
            "givenName": "Juha", 
            "id": "sg:person.01106523057.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106523057.35"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.452861.c", 
              "name": [
                "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nguyen", 
            "givenName": "Elizabeth V.", 
            "id": "sg:person.01323653654.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323653654.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.452861.c", 
              "name": [
                "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Moulder", 
            "givenName": "Robert", 
            "id": "sg:person.01160467712.17", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160467712.17"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA", 
              "id": "http://www.grid.ac/institutes/grid.411024.2", 
              "name": [
                "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland", 
                "Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Goodlett", 
            "givenName": "David R.", 
            "id": "sg:person.01044126157.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044126157.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.452861.c", 
              "name": [
                "Turku Centre for Biotechnology, University of Turku and \u00c5bo Akademi University, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lahesmaa", 
            "givenName": "Riitta", 
            "id": "sg:person.0767010034.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767010034.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland", 
              "id": "http://www.grid.ac/institutes/grid.410552.7", 
              "name": [
                "Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carp\u00e9n", 
            "givenName": "Olli", 
            "id": "sg:person.01345057137.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345057137.09"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/cddis.2013.428", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009401093", 
              "https://doi.org/10.1038/cddis.2013.428"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt.1754", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019307928", 
              "https://doi.org/10.1038/nbt.1754"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2011.611", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038523682", 
              "https://doi.org/10.1038/onc.2011.611"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1202540", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028453288", 
              "https://doi.org/10.1038/sj.onc.1202540"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2164-14-508", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016304247", 
              "https://doi.org/10.1186/1471-2164-14-508"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-006-0325-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002295545", 
              "https://doi.org/10.1007/s00280-006-0325-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/gb-2012-13-10-r87", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050578553", 
              "https://doi.org/10.1186/gb-2012-13-10-r87"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/gb-2012-13-10-r92", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050959661", 
              "https://doi.org/10.1186/gb-2012-13-10-r92"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrclinonc.2015.224", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027476506", 
              "https://doi.org/10.1038/nrclinonc.2015.224"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2164-15-539", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012480827", 
              "https://doi.org/10.1186/1471-2164-15-539"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc3691", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052056915", 
              "https://doi.org/10.1038/nrc3691"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/srep22190", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017471491", 
              "https://doi.org/10.1038/srep22190"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1755-8794-2-34", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001301177", 
              "https://doi.org/10.1186/1755-8794-2-34"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13073-015-0210-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019612549", 
              "https://doi.org/10.1186/s13073-015-0210-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-005-0059-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001043909", 
              "https://doi.org/10.1007/s00280-005-0059-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1755-8794-1-47", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001997616", 
              "https://doi.org/10.1186/1755-8794-1-47"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-007-0674-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037911838", 
              "https://doi.org/10.1007/s00280-007-0674-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00109-016-1395-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031213155", 
              "https://doi.org/10.1007/s00109-016-1395-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nmeth.1923", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006541515", 
              "https://doi.org/10.1038/nmeth.1923"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc4019", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019760275", 
              "https://doi.org/10.1038/nrc4019"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt.1630", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023421025", 
              "https://doi.org/10.1038/nbt.1630"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12885-015-1101-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008633606", 
              "https://doi.org/10.1186/s12885-015-1101-8"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-05-04", 
        "datePublishedReg": "2017-05-04", 
        "description": "High-grade serous ovarian cancer is the most common ovarian cancer type. Although the combination of surgery and platinum-taxane chemotherapy provide an effective treatment, drug resistance frequently occurs leading to poor outcome. In order to clarify the molecular mechanisms of drug resistance, the DNA methylation and transcriptomic changes, associated with the development of drug resistance in high-grade serous ovarian cancer, were examined from patient derived malignant ascites cells. In parallel with large-scale transcriptome changes, cisplatin resistance was associated with loss of hypermethylation at several CpG sites primarily localized in the intergenic regions of the genome. The transcriptome and CpG methylome changes in response to cisplatin treatment of both sensitive and resistant cells were minimal, indicating the importance of post-translational mechanisms in regulating death or survival of the cells. The response of resistant cells to high concentrations of cisplatin revealed transcriptomic changes in potential key drivers of drug resistance, such as KLF4. Among the strongest changes was also induction of IL6 in resistant cells and the expression was further increased in response to cisplatin. Also, several other components of IL6 signaling were affected, further supporting previous observations on its importance in malignant transformation and development of drug resistance in ovarian cancer.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41598-017-01624-4", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.4245674", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1045337", 
            "issn": [
              "2045-2322"
            ], 
            "name": "Scientific Reports", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "7"
          }
        ], 
        "keywords": [
          "high-grade serous ovarian cancer", 
          "serous ovarian cancer", 
          "ovarian cancer", 
          "drug resistance", 
          "resistant cells", 
          "cisplatin resistance", 
          "platinum-taxane chemotherapy", 
          "malignant ascites cells", 
          "combination of surgery", 
          "ovarian cancer types", 
          "induction of IL6", 
          "poor outcome", 
          "effective treatment", 
          "transcriptomic changes", 
          "transcriptome changes", 
          "malignant transformation", 
          "DNA methylation", 
          "cancer types", 
          "large-scale transcriptome changes", 
          "cancer", 
          "IL6", 
          "post-translational mechanisms", 
          "cisplatin", 
          "ascites cells", 
          "molecular mechanisms", 
          "methylome changes", 
          "cells", 
          "treatment", 
          "intergenic region", 
          "potential key drivers", 
          "CpG sites", 
          "response", 
          "chemotherapy", 
          "surgery", 
          "previous observations", 
          "high concentrations", 
          "death", 
          "methylation", 
          "survival", 
          "outcomes", 
          "resistance", 
          "changes", 
          "induction", 
          "hypermethylation", 
          "expression", 
          "transcriptome", 
          "mechanism", 
          "genome", 
          "KLF4", 
          "key drivers", 
          "development", 
          "loss", 
          "importance", 
          "concentration", 
          "strong changes", 
          "combination", 
          "sites", 
          "types", 
          "region", 
          "drivers", 
          "observations", 
          "components", 
          "parallel", 
          "transformation", 
          "order"
        ], 
        "name": "DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer", 
        "pagination": "1469", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1085131720"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41598-017-01624-4"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "28473707"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41598-017-01624-4", 
          "https://app.dimensions.ai/details/publication/pub.1085131720"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T21:02", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_748.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41598-017-01624-4"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41598-017-01624-4'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41598-017-01624-4'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41598-017-01624-4'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41598-017-01624-4'


     

    This table displays all metadata directly associated to this object as RDF triples.

    330 TRIPLES      21 PREDICATES      125 URIs      95 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41598-017-01624-4 schema:about N0fa90c89e90142b7a22d5240267a3be8
    2 N1392331478b84f7ca06bb425eb2fe021
    3 N2414eb7b7d57415c8d1a2646cdbc2cd0
    4 N29d655d7698a4ce99c33bb21b0c4b83e
    5 N52f7a62e557d48808960ec85c6c41163
    6 N68b9ba0d5a664ce8b2babf6d6bdb793c
    7 N8280921b1db746938a273255b1b22e55
    8 N86d38799287c40fbb325a0362704a466
    9 N9025280a673d4128829c1d6cc19a5e29
    10 N974d2e0427d543d489d8333794ea7284
    11 Ned6b055d36cb4ef5b4a84f26eeade254
    12 Nf66b68a1ec70470483762ee69b8e808e
    13 Nfd9b9e5e77364d1f9422fb71b0775779
    14 anzsrc-for:11
    15 anzsrc-for:1112
    16 schema:author N88da708d83774e92b0125191ef443fe7
    17 schema:citation sg:pub.10.1007/s00109-016-1395-2
    18 sg:pub.10.1007/s00280-005-0059-7
    19 sg:pub.10.1007/s00280-006-0325-3
    20 sg:pub.10.1007/s00280-007-0674-6
    21 sg:pub.10.1038/cddis.2013.428
    22 sg:pub.10.1038/nbt.1630
    23 sg:pub.10.1038/nbt.1754
    24 sg:pub.10.1038/nmeth.1923
    25 sg:pub.10.1038/nrc3691
    26 sg:pub.10.1038/nrc4019
    27 sg:pub.10.1038/nrclinonc.2015.224
    28 sg:pub.10.1038/onc.2011.611
    29 sg:pub.10.1038/sj.onc.1202540
    30 sg:pub.10.1038/srep22190
    31 sg:pub.10.1186/1471-2164-14-508
    32 sg:pub.10.1186/1471-2164-15-539
    33 sg:pub.10.1186/1755-8794-1-47
    34 sg:pub.10.1186/1755-8794-2-34
    35 sg:pub.10.1186/gb-2012-13-10-r87
    36 sg:pub.10.1186/gb-2012-13-10-r92
    37 sg:pub.10.1186/s12885-015-1101-8
    38 sg:pub.10.1186/s13073-015-0210-y
    39 schema:datePublished 2017-05-04
    40 schema:datePublishedReg 2017-05-04
    41 schema:description High-grade serous ovarian cancer is the most common ovarian cancer type. Although the combination of surgery and platinum-taxane chemotherapy provide an effective treatment, drug resistance frequently occurs leading to poor outcome. In order to clarify the molecular mechanisms of drug resistance, the DNA methylation and transcriptomic changes, associated with the development of drug resistance in high-grade serous ovarian cancer, were examined from patient derived malignant ascites cells. In parallel with large-scale transcriptome changes, cisplatin resistance was associated with loss of hypermethylation at several CpG sites primarily localized in the intergenic regions of the genome. The transcriptome and CpG methylome changes in response to cisplatin treatment of both sensitive and resistant cells were minimal, indicating the importance of post-translational mechanisms in regulating death or survival of the cells. The response of resistant cells to high concentrations of cisplatin revealed transcriptomic changes in potential key drivers of drug resistance, such as KLF4. Among the strongest changes was also induction of IL6 in resistant cells and the expression was further increased in response to cisplatin. Also, several other components of IL6 signaling were affected, further supporting previous observations on its importance in malignant transformation and development of drug resistance in ovarian cancer.
    42 schema:genre article
    43 schema:isAccessibleForFree true
    44 schema:isPartOf N5bfed3ae3fb84c5fb7ebe8955467d3aa
    45 Nbd5b7778b5604b4ab8d0ae68ed8d75a2
    46 sg:journal.1045337
    47 schema:keywords CpG sites
    48 DNA methylation
    49 IL6
    50 KLF4
    51 ascites cells
    52 cancer
    53 cancer types
    54 cells
    55 changes
    56 chemotherapy
    57 cisplatin
    58 cisplatin resistance
    59 combination
    60 combination of surgery
    61 components
    62 concentration
    63 death
    64 development
    65 drivers
    66 drug resistance
    67 effective treatment
    68 expression
    69 genome
    70 high concentrations
    71 high-grade serous ovarian cancer
    72 hypermethylation
    73 importance
    74 induction
    75 induction of IL6
    76 intergenic region
    77 key drivers
    78 large-scale transcriptome changes
    79 loss
    80 malignant ascites cells
    81 malignant transformation
    82 mechanism
    83 methylation
    84 methylome changes
    85 molecular mechanisms
    86 observations
    87 order
    88 outcomes
    89 ovarian cancer
    90 ovarian cancer types
    91 parallel
    92 platinum-taxane chemotherapy
    93 poor outcome
    94 post-translational mechanisms
    95 potential key drivers
    96 previous observations
    97 region
    98 resistance
    99 resistant cells
    100 response
    101 serous ovarian cancer
    102 sites
    103 strong changes
    104 surgery
    105 survival
    106 transcriptome
    107 transcriptome changes
    108 transcriptomic changes
    109 transformation
    110 treatment
    111 types
    112 schema:name DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer
    113 schema:pagination 1469
    114 schema:productId N1a03ddf6ea4b4dfdb86803e16d2ff231
    115 N58e026bdf5654fb688faa0954b9f55cc
    116 Ne7d1b59f2cbe4ce4b5cdb76988aefcde
    117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085131720
    118 https://doi.org/10.1038/s41598-017-01624-4
    119 schema:sdDatePublished 2022-11-24T21:02
    120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    121 schema:sdPublisher N92684fb193484270b78432dd45f3e3d3
    122 schema:url https://doi.org/10.1038/s41598-017-01624-4
    123 sgo:license sg:explorer/license/
    124 sgo:sdDataset articles
    125 rdf:type schema:ScholarlyArticle
    126 N0fa90c89e90142b7a22d5240267a3be8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Kruppel-Like Factor 4
    128 rdf:type schema:DefinedTerm
    129 N1392331478b84f7ca06bb425eb2fe021 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Transcriptome
    131 rdf:type schema:DefinedTerm
    132 N1a03ddf6ea4b4dfdb86803e16d2ff231 schema:name dimensions_id
    133 schema:value pub.1085131720
    134 rdf:type schema:PropertyValue
    135 N2414eb7b7d57415c8d1a2646cdbc2cd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name CpG Islands
    137 rdf:type schema:DefinedTerm
    138 N29d655d7698a4ce99c33bb21b0c4b83e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Cell Line, Tumor
    140 rdf:type schema:DefinedTerm
    141 N3dc06900fed54e64ad30f3f51c2f5554 rdf:first sg:person.01345057137.09
    142 rdf:rest rdf:nil
    143 N481fd755fc0c4f649495b342eee93c49 rdf:first sg:person.0770257425.21
    144 rdf:rest N67c21dfea1034628bcc2e57a2d86beb5
    145 N4b3cfa2ea1984acbb01b6087dfdf1329 rdf:first sg:person.01160467712.17
    146 rdf:rest Nb44260a8a6014adca38d83cfbe846b0c
    147 N52f7a62e557d48808960ec85c6c41163 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Ovarian Neoplasms
    149 rdf:type schema:DefinedTerm
    150 N58e026bdf5654fb688faa0954b9f55cc schema:name doi
    151 schema:value 10.1038/s41598-017-01624-4
    152 rdf:type schema:PropertyValue
    153 N5bfed3ae3fb84c5fb7ebe8955467d3aa schema:issueNumber 1
    154 rdf:type schema:PublicationIssue
    155 N67c21dfea1034628bcc2e57a2d86beb5 rdf:first sg:person.01344256713.18
    156 rdf:rest Nd876de04a2da4fd0bf1cce2afea192f7
    157 N68b9ba0d5a664ce8b2babf6d6bdb793c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Signal Transduction
    159 rdf:type schema:DefinedTerm
    160 N8280921b1db746938a273255b1b22e55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Female
    162 rdf:type schema:DefinedTerm
    163 N86d38799287c40fbb325a0362704a466 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Drug Resistance, Neoplasm
    165 rdf:type schema:DefinedTerm
    166 N88da708d83774e92b0125191ef443fe7 rdf:first sg:person.01174612030.78
    167 rdf:rest N481fd755fc0c4f649495b342eee93c49
    168 N9025280a673d4128829c1d6cc19a5e29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Antineoplastic Agents
    170 rdf:type schema:DefinedTerm
    171 N92684fb193484270b78432dd45f3e3d3 schema:name Springer Nature - SN SciGraph project
    172 rdf:type schema:Organization
    173 N95421a95582f46c782bd6b7cb71299ca rdf:first sg:person.0767010034.41
    174 rdf:rest N3dc06900fed54e64ad30f3f51c2f5554
    175 N974d2e0427d543d489d8333794ea7284 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name DNA Methylation
    177 rdf:type schema:DefinedTerm
    178 Nb44260a8a6014adca38d83cfbe846b0c rdf:first sg:person.01044126157.13
    179 rdf:rest N95421a95582f46c782bd6b7cb71299ca
    180 Nb949e3eb60a24a6eb643c0b06bdb7649 rdf:first sg:person.01323653654.16
    181 rdf:rest N4b3cfa2ea1984acbb01b6087dfdf1329
    182 Nbd5b7778b5604b4ab8d0ae68ed8d75a2 schema:volumeNumber 7
    183 rdf:type schema:PublicationVolume
    184 Nd876de04a2da4fd0bf1cce2afea192f7 rdf:first sg:person.01106523057.35
    185 rdf:rest Nb949e3eb60a24a6eb643c0b06bdb7649
    186 Ne7d1b59f2cbe4ce4b5cdb76988aefcde schema:name pubmed_id
    187 schema:value 28473707
    188 rdf:type schema:PropertyValue
    189 Ned6b055d36cb4ef5b4a84f26eeade254 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Gene Expression Regulation, Neoplastic
    191 rdf:type schema:DefinedTerm
    192 Nf66b68a1ec70470483762ee69b8e808e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Cisplatin
    194 rdf:type schema:DefinedTerm
    195 Nfd9b9e5e77364d1f9422fb71b0775779 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Humans
    197 rdf:type schema:DefinedTerm
    198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    199 schema:name Medical and Health Sciences
    200 rdf:type schema:DefinedTerm
    201 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    202 schema:name Oncology and Carcinogenesis
    203 rdf:type schema:DefinedTerm
    204 sg:grant.4245674 http://pending.schema.org/fundedItem sg:pub.10.1038/s41598-017-01624-4
    205 rdf:type schema:MonetaryGrant
    206 sg:journal.1045337 schema:issn 2045-2322
    207 schema:name Scientific Reports
    208 schema:publisher Springer Nature
    209 rdf:type schema:Periodical
    210 sg:person.01044126157.13 schema:affiliation grid-institutes:grid.411024.2
    211 schema:familyName Goodlett
    212 schema:givenName David R.
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044126157.13
    214 rdf:type schema:Person
    215 sg:person.01106523057.35 schema:affiliation grid-institutes:grid.410552.7
    216 schema:familyName Rantala
    217 schema:givenName Juha
    218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106523057.35
    219 rdf:type schema:Person
    220 sg:person.01160467712.17 schema:affiliation grid-institutes:grid.452861.c
    221 schema:familyName Moulder
    222 schema:givenName Robert
    223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160467712.17
    224 rdf:type schema:Person
    225 sg:person.01174612030.78 schema:affiliation grid-institutes:grid.452861.c
    226 schema:familyName Lund
    227 schema:givenName Riikka J.
    228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174612030.78
    229 rdf:type schema:Person
    230 sg:person.01323653654.16 schema:affiliation grid-institutes:grid.452861.c
    231 schema:familyName Nguyen
    232 schema:givenName Elizabeth V.
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323653654.16
    234 rdf:type schema:Person
    235 sg:person.01344256713.18 schema:affiliation grid-institutes:grid.452861.c
    236 schema:familyName Salmi
    237 schema:givenName Jussi
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344256713.18
    239 rdf:type schema:Person
    240 sg:person.01345057137.09 schema:affiliation grid-institutes:grid.410552.7
    241 schema:familyName Carpén
    242 schema:givenName Olli
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345057137.09
    244 rdf:type schema:Person
    245 sg:person.0767010034.41 schema:affiliation grid-institutes:grid.452861.c
    246 schema:familyName Lahesmaa
    247 schema:givenName Riitta
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767010034.41
    249 rdf:type schema:Person
    250 sg:person.0770257425.21 schema:affiliation grid-institutes:grid.410552.7
    251 schema:familyName Huhtinen
    252 schema:givenName Kaisa
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770257425.21
    254 rdf:type schema:Person
    255 sg:pub.10.1007/s00109-016-1395-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031213155
    256 https://doi.org/10.1007/s00109-016-1395-2
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1007/s00280-005-0059-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001043909
    259 https://doi.org/10.1007/s00280-005-0059-7
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1007/s00280-006-0325-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002295545
    262 https://doi.org/10.1007/s00280-006-0325-3
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1007/s00280-007-0674-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037911838
    265 https://doi.org/10.1007/s00280-007-0674-6
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/cddis.2013.428 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009401093
    268 https://doi.org/10.1038/cddis.2013.428
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/nbt.1630 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023421025
    271 https://doi.org/10.1038/nbt.1630
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/nbt.1754 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019307928
    274 https://doi.org/10.1038/nbt.1754
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/nmeth.1923 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006541515
    277 https://doi.org/10.1038/nmeth.1923
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1038/nrc3691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052056915
    280 https://doi.org/10.1038/nrc3691
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1038/nrc4019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019760275
    283 https://doi.org/10.1038/nrc4019
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1038/nrclinonc.2015.224 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027476506
    286 https://doi.org/10.1038/nrclinonc.2015.224
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1038/onc.2011.611 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038523682
    289 https://doi.org/10.1038/onc.2011.611
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1038/sj.onc.1202540 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028453288
    292 https://doi.org/10.1038/sj.onc.1202540
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1038/srep22190 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017471491
    295 https://doi.org/10.1038/srep22190
    296 rdf:type schema:CreativeWork
    297 sg:pub.10.1186/1471-2164-14-508 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016304247
    298 https://doi.org/10.1186/1471-2164-14-508
    299 rdf:type schema:CreativeWork
    300 sg:pub.10.1186/1471-2164-15-539 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012480827
    301 https://doi.org/10.1186/1471-2164-15-539
    302 rdf:type schema:CreativeWork
    303 sg:pub.10.1186/1755-8794-1-47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001997616
    304 https://doi.org/10.1186/1755-8794-1-47
    305 rdf:type schema:CreativeWork
    306 sg:pub.10.1186/1755-8794-2-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001301177
    307 https://doi.org/10.1186/1755-8794-2-34
    308 rdf:type schema:CreativeWork
    309 sg:pub.10.1186/gb-2012-13-10-r87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050578553
    310 https://doi.org/10.1186/gb-2012-13-10-r87
    311 rdf:type schema:CreativeWork
    312 sg:pub.10.1186/gb-2012-13-10-r92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050959661
    313 https://doi.org/10.1186/gb-2012-13-10-r92
    314 rdf:type schema:CreativeWork
    315 sg:pub.10.1186/s12885-015-1101-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008633606
    316 https://doi.org/10.1186/s12885-015-1101-8
    317 rdf:type schema:CreativeWork
    318 sg:pub.10.1186/s13073-015-0210-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1019612549
    319 https://doi.org/10.1186/s13073-015-0210-y
    320 rdf:type schema:CreativeWork
    321 grid-institutes:grid.410552.7 schema:alternateName Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland
    322 schema:name Department of Pathology, Medicity Research Unit, University of Turku and Turku University Hospital, Turku, Finland
    323 rdf:type schema:Organization
    324 grid-institutes:grid.411024.2 schema:alternateName Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA
    325 schema:name Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA
    326 Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland
    327 rdf:type schema:Organization
    328 grid-institutes:grid.452861.c schema:alternateName Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland
    329 schema:name Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland
    330 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...